紫杉醇DCB治疗老年人原发冠脉病变的安全性和有效性探讨  

Safety and Efficacy of Paclitaxel DCB in the Treatment of Primary Coronary Artery Disease in the Elderly

作　　者：鲁玮 孟亮[1] 陈曦 李敬[1] LU Wei;MENG Liang;CHEN Xi;LI Jing(Department of Cardiovascular Medicine,Affiliated Central Hospital of Shenyang Medical College,Liaoyang City,Liaoning Shenyang 110024)

机构地区：[1]辽阳市沈阳医学院附属中心医院心血管内科,辽宁沈阳110024

出　　处：《中国医疗器械信息》2022年第22期163-165,共3页China Medical Device Information

摘　　要：目的:探讨在老年原发冠状病变的治疗中,紫杉醇DCB(药物涂层球囊)治疗的有效性和安全性。方法:使用随机抽签法从2016年8月~2019年7月于本院进行治疗的老年原发冠状病变患者中选取58例,并以奇偶数法分为两组,实验组(n=29,紫杉醇DCB疗法)与参照组(n=29,药物洗脱支架治疗)。结果:实验组患者的不良事件和再狭窄发生率均低于参照组;治疗前两组患者最小管腔直径无明显差异,治疗后实验组患者最小管腔直径显著高于参照组(P<0.05)。结论:紫杉醇DCB能够有效治疗老年原发冠状病变,改善管腔直径、预防再狭窄,且具有较高的安全性。Objective:To explore the effectiveness and safety of paclitaxel DCB(drug coated balloon)in the treatment of primary coronary lesions in the elderly.Methods:Using the random lottery method,58 elderly patients with primary coronary lesions treated in our hospital from August 2016 to July 2019 were selected and divided into two groups,experimental group(n=29,paclitaxel DCB therapy)and reference group(n=29,drug-eluting stent treatment).Results:The incidence of adverse events and restenosis in the experimental group was lower than that in the reference group.There was no significant difference in the minimum lumen diameter between the two groups before treatment,but the minimum lumen diameter of the experimental group was significantly higher than that of the reference group after treatment(P<0.05).Conclusion:Paclitaxel DCB can effectively treat senile primary coronary lesions,improve lumen diameter,prevent restenosis,and has high safety.

关 键 词：紫杉醇DCB 原发冠脉病变 临床疗效 治疗有效性 

分 类 号：R541.4[医药卫生—心血管疾病]